1. Wang, Yue, Zhang, Menghan, Bi, Ran, Cao, Qiuhua, Gao, Xinghua. 2022. ACSL4 deficiency confers protection against ferroptosis-mediated acute kidney injury. In Redox biology, 51, 102262. doi:10.1016/j.redox.2022.102262. https://pubmed.ncbi.nlm.nih.gov/35180475/
2. Tuo, Qing-Zhang, Liu, Yu, Xiang, Zheng, Dong, Biao, Lei, Peng. 2022. Thrombin induces ACSL4-dependent ferroptosis during cerebral ischemia/reperfusion. In Signal transduction and targeted therapy, 7, 59. doi:10.1038/s41392-022-00917-z. https://pubmed.ncbi.nlm.nih.gov/35197442/
3. Chen, Junru, Ding, Chaofeng, Chen, Yunhao, Wu, Jian, Zheng, Shusen. 2020. ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway. In Cancer letters, 502, 154-165. doi:10.1016/j.canlet.2020.12.019. https://pubmed.ncbi.nlm.nih.gov/33340617/
4. Yuan, Hua, Li, Xuemei, Zhang, Xiuying, Kang, Rui, Tang, Daolin. 2016. Identification of ACSL4 as a biomarker and contributor of ferroptosis. In Biochemical and biophysical research communications, 478, 1338-43. doi:10.1016/j.bbrc.2016.08.124. https://pubmed.ncbi.nlm.nih.gov/27565726/
5. Duan, Jingjing, Wang, Zhuo, Duan, Ran, Chen, Zhen, Yang, Yong. 2021. Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice. In Hepatology (Baltimore, Md.), 75, 140-153. doi:10.1002/hep.32148. https://pubmed.ncbi.nlm.nih.gov/34510514/
6. Gao, Li, Zhang, Junsheng, Yang, Tingting, Meng, Xiao-Ming, Wu, Yonggui. 2023. STING/ACSL4 axis-dependent ferroptosis and inflammation promote hypertension-associated chronic kidney disease. In Molecular therapy : the journal of the American Society of Gene Therapy, 31, 3084-3103. doi:10.1016/j.ymthe.2023.07.026. https://pubmed.ncbi.nlm.nih.gov/37533255/
7. Zeng, Kaixuan, Li, Weihao, Wang, Yue, Xing, Yue, Zhou, Chi. 2023. Inhibition of CDK1 Overcomes Oxaliplatin Resistance by Regulating ACSL4-mediated Ferroptosis in Colorectal Cancer. In Advanced science (Weinheim, Baden-Wurttemberg, Germany), 10, e2301088. doi:10.1002/advs.202301088. https://pubmed.ncbi.nlm.nih.gov/37428466/